分子伙伴和Orano Med扩大癌症治疗伙伴关系,规划2025年试验。 Molecular Partners and Orano Med expand cancer therapy partnership, planning 2025 trials.

分子伙伴和Orano Med扩大了伙伴关系,利用名为212Pb-Radio-DARPins的新型药物开发有针对性的癌症疗法。 Molecular Partners and Orano Med have expanded their partnership to develop targeted cancer therapies using a new class of drugs called 212Pb-Radio-DARPins. 目前的合作涵盖10个方案,计划在2025年开始对主要候选人MP0712进行临床试验。 The collaboration now covers ten programs, with plans to start clinical trials for the lead candidate MP0712 in 2025. 分子伙伴将牵头制定六个新方案,将其独特的药物平台与Orano Med的放射性材料和发展专长结合起来。 Molecular Partners will lead development of six new programs, integrating their unique drug platform with Orano Med's radioactive materials and development expertise.